Aquestive Therapeutics Inc Investor & Analyst Libervant Update Forum and Webcast Transcript
Joining Aquestive today. As we committed, we're here today to share with you the clinical data related to Libervant. Our buccal lead delivered diazepam-based product candidate.
More importantly, we're here to demonstrate why we believe we've provided the FDA with all of the appropriate data in response to the questions they had at our pre-NDA meeting a year ago this December.
Since Libervant is the focus today, I want to be clear, and so everybody's expectations -- we'll not be providing a general update about our business or respond to questions outside the content of the program, so I'd ask you please to limit yourselves. We want to stay focused on the exciting clinical, regulatory and scientific data presented on Libervant today.
As you all know, Aquestive filed -- completed its filing for its NDA for Libervant on November 22. We're excited the submission is complete, and we await the first feedback from the FDA regarding its acceptance in a few weeks. We've gathered a group of experts here to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |